anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Non-communicable diseases are becoming a challenge for the health care system in Ethiopia, which has suffered a double burden from infectious and rapidly increasing non-communicable diseases. However, there is little information on health-promoting behavior in the study settings. Thus, the purpose of this study was to determine health-promoting behaviors and its associated factors among adult's residents of Gedeo zone.
METHODS: A cross-sectional study was conducted among 705 adult residents of Gedeo zone, south Ethiopia, selected using a multi-stage sampling technique. Interviews administered through a structured questionnaire were used to collect the data. The data were entered using Kobo Collect and analyzed using Stata version 17. The baseline characteristics of the participants were summarized using descriptive statistics. The independent sample t-test and one-way ANOVA were used to compare two groups and more than two groups, respectively. Stepwise multiple linear regression analysis was used to identify the potential determinants of health-promoting behavior and its components. Statistically significant factors were declared at p-value of less than or equal to 0.05.
RESULTS: The overall means score for health-promoting behavior was 73.88 ± 16.79. Physical activity and spiritual growth had the lowest and highest mean scores, respectively. The variables: gender, marital status, education, family history of NCDs, health insurance status, perceived health status, knowledge of NCD risk factors, risk perception of NCDs, expected outcome, cues to action, and self-efficacy showed a statistically significant difference in overall health-promoting behavior. The total health-promoting behavior score was associated with age, gender, perceived health status, marital status, family history of NCDs, health insurance, knowledge of NCD risk factors, perceived threat, expected outcome, self-efficacy, and cues to action.
CONCLUSION AND RECOMMENDATIONS: In the study, the mean score of health-promoting behaviors was low. Socio-demographic and economic variables, family history of NCD, perceived health status, knowledge of NCD risk factors, perceived threat, expected outcome, self-efficacy, and cues to action affect health-promoting behaviors. Therefore, the study suggests establishing health promotion programs to increase residents' awareness of health-promoting lifestyles, empower them to adopt healthy lifestyles, and improve health outcomes by increasing self-efficacy, providing education, and creating supportive environments.
PURPOSE: To describe a cohort with a high risk of recurrence who received bezlotoxumab during the first episode of Clostridioides difficile infection (CDI) and to compare this cohort with patients with similar characteristics who did not receive the monoclonal antibody.
METHODS: A prospective and multicentre study of patients with a high risk of recurrence (expected recurrence rate>35%) who were treated with bezlotoxumab during their first episode of CDI was conducted. A propensity score-matched model 1:2 was used to compare both cohorts that were weighed according to basal characteristics (hospital-acquisition, creatinine value, and fidaxomicin as a CDI treatment).
RESULTS: Sixty patients (mean age:72 years) were prospectively treated with bezlotoxumab plus anti-Clostridioides antibiotic therapy. Vancomycin (48 patients) and fidaxomicin (12 patients) were prescribed for CDI treatment, and bezlotoxumab was administered at a mean of 4.2 (SD:2.1) days from the beginning of therapy. Recurrence occurred in nine out of 54 (16.7%) evaluable patients at 8 weeks. Forty bezlotoxumab-treated patients were matched with 69 non-bezlotoxumab-treated patients. Recurrence rates at 12 weeks were 15.0% (6/40) in bezlotoxumab-treated patients vs. 23.2% (16/69) in non-bezlotoxumab-treated patients (OR:0.58 [0.20-1.65]). No adverse effects were observed related to bezlotoxumab infusion. Only one of 9 patients with previous heart failure developed heart failure.
CONCLUSION: We observed that patients treated with bezlotoxumab in a real-world setting during a first episode of CDI having high risk of recurrence, presented low rate of recurrence. However, a significant difference in recurrence could not be proved in comparison to the controls. We did not detect any other safety concerns.
NEW MATERIAL:A biologically active substance obtained from Tritonia crocosmeflora Lemoine (Elementary analysis; C, 53.2%; H, 7.8%; N, 0%. Constituent sugar; Rhamnose, fucose, arabinose, xylose and glucose. Solubility; Soluble in water and methanol and insoluble in acetone and ether. pH exhibited by 1% aqueous solution; 5pH. Color reaction; Positive to phenol-sulfuric acid reagent reaction and Liebermann reaction. Hue; White. Constituent sapogenin; Medicagenic acid and polygalacic acid). USE:A remedy for cancer. PREPARATION:A bulb of Tritonia crocosmaeflora Lemoine is extracted with methanol, and the resultant extract is concentrated. Water is then added thereto to dissolve the extract. Acetone is then added to the solution to separate and purify the aimed substance from the formed precipitate or water is added to the above-mentioned concentrate to remove insoluble materials. The soluble part is then dialyzed to separate and purify the aimed substance from the inner dialyzate and give the aimed biologically active substance.
It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the growth cycle of non-small cell lung cancer cells. Without being bound by theory, it is an object of the present invention that the nicotinic receptor antagonists disclosed herein are believed to possess reversible binding properties. Moreover, the compounds of the present invention are selective for 0.7 nAChR. For example, the compounds of the present invention are not believed to bind to 0.4 (32 nAChR neuromuscular receptors. It is also contemplated that the nicotinic receptor antagonists of the present invention will be used as a counter measure to treat exposure, or potential exposure, to a wide array of potential neurotoxins.
FIELD: biotechnology, immunology, oncology. SUBSTANCE: invention relates with new highly effective biospecific antibody fragments which recognize antigen of lymphocytes CD2 and any variable tumor antigen. Also, invention relates with two new monoclonal antibodies designated as AIC02.M1 and AIC02. M2. Combination of these antibodies one of which at least is biospecific antibody fragment and can be used in therapy and diagnosis of tumors successfully. EFFECT: biospecific antibodies indicated above.
16 patients (6 ambulant and 10 non ambulant), affected by type II and type III SMA will be enrolled and assessed at baseline and 6 and 12 months later. Non ambulant patients will be assessed using the modified version of the Hammersmith Motor Functional Scale while ambulant patients will be assessed using the extended module of the Hammersmith Motor Functional Scale and timed items, the 6 minute walk and a step activity monitor. All patients will also be assessed using the Motor Function Measure (MFM), that covers the whole range of activities for both ambulant and non ambulant patients. All measures will undergo a process of validation including inter observer reliability. This information will be most valuable for any future trial and will make the groups involved ready to participate to future collaborative studies saving a lot of time on the preliminary aspects (validation, reliability, training) that will be fulfilled by the present study. The study will also provide natural history data for a 12 month period on patients with SMA II and III.
A supplement including a blend of turmeric, quercetin and rosemary, or holy basil, wasabi, and broccoli seed extract which are present in a balanced and predetermined ratio, and which stimulate the Antioxidant Response Element (ARE), Quinone Reductase, and/or induce related gene expression, for example, heme oxygenase-1 (HMOX-1) expression. The blend of ingredients can be formed as or in a dietary supplement adapted for administration to a subject. The dietary supplement can be formulated so that the turmeric, quercetin and rosemary are present in a predetermined ratio of 1:3:5, or holy basil, wasabi, and broccoli seed extract in a predetermined ratio of 1:1:0.2. Additional ingredients can be included in the supplement. The supplement can synergistically affect natural antioxidant response pathways within cells of a subject to whom the supplement is administered. A related method of use is also provided.
Subjects will be tested on two different days, first day will be baseline and Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin) and second day will be Placebo. Testing will take place one-hour after BH4/placebo intake. There will be a 2-week washout between testing days.
It is a comprehensive self-guided Internet-based cognitive-behavioral therapy (CBT) that includes three components: (1) the myWHI diary. (2) 30 multi-media learning topics that the user is encouraged to go through in a sequential way. The topics contain education information and teach strategies to cope better with their headaches.
NEW MATERIAL:The isoflavan derivative of formula (R1 is methyl; R2 is methyl or H). USE:Useful as a muscle relaxant. It has microcirculation improving action and exhibits hypotensive action against essential hypertension, coronary vasodilating action, cerebral circulation improving action, action to ameliorate peripheral blood flow disorder (Raynaud's disease, Buerger disease etc.), etc. PREPARATION:KANZO (Glycyrrhiza glauba) is immersed in an organic solvent, the extract is treated by liquid chromatography an the compound of formula is separated from the eluate. The organic solvent is methanol, ethanol, acetone, etc., or their mixture. KANZO is a leguminous plant and its root and stolon have been long used as herb drugs.
An integrated health record system comprises a platform including a processor coupled to a medical application. The system includes at least one input device coupled to the processor. The input device receives patient information of a patient via an electronic form and receives vital signs of the patient. The medical application integrates the patient information and the vital signs into an electronic health record (EHR) that corresponds to the patient. The medical application receives a sound file that includes information resulting from an examination of the patient, and translates the sound file into a document that comprises a clinical document architecture (CDA). The medical application parses the document and identifies a plurality of data components based on a correspondence to a plurality of data fields of the HER. The medical application populates each of the plurality of data fields with each of the data components.
The advent of high-throughput sequencing in clinical microbiology is opening the way to new diagnostic and prognostic approaches in infectious diseases. Detection, identification and characterisation of pathogenic microorganisms are essential steps in diagnosis and implementation of appropriate antimicrobial therapy. However, standard methods of microbiological diagnosis are failing in some cases. In addition, the emergence of new infections, facilitated by international travel and global warming, requires the implementation of innovative diagnostic methods. Among the different strategies used in clinical microbiology and reviewed in this article, shotgun metagenomics is the only technique that allows today a panpathogenic and unbiased detection of all microorganisms potentially responsible for an infectious disease, including those still unknown. The aims of this article are to present the different possible strategies of high-throughput sequencing used in the microbiological diagnosis of infectious diseases and to highlight the diagnostic contribution of shotgun metagenomics in the field of central nervous system infections.
PROBLEM TO BE SOLVED: To provide a cosmetic composition containing Red No. 218 and exhibiting at least two phases, an oil phase and a water phase, when left still standing, which cosmetic composition prevents Red No. 218 from developing the color after being produced and keeps the state until application in use.SOLUTION: There is provided a cosmetic composition containing the following components A to C and comprising at least two phases: (component A) Red No. 218; (component B) a nonionic surface-active agent comprising a polymer of polypropyleneglycol or polyethyleneglycol in the molecule with a weight average molecular weight of 1000 or more; and (component C) a polyalcohol. Preferably, the component C further includes glycerin, and the component B is more preferably a dipolyhydroxyfatty acid polyethyleneglycol. In addition, the cosmetic composition preferably contains an ester oil in the oil phase.EFFECT: The cosmetic composition exhibits an extremely good color tone stability such that Red No. 218 does not develop the color until the cosmetic composition is applied to the skin in use but develops the color upon application.SELECTED DRAWING: None
Clevidipine (0.5 mg/mL in 20% lipid emulsion) will be administered in an open-label fashion intravenously to all patients randomized to the clevidipine arm in Stage 2, following the same dosing instructions as in the clevidipine arm in Stage 1. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
Obstructive sleep apnea (OSA), characterized by episodes of intermittent hypoxia (IH), is highly prevalent in patients with abdominal aortic aneurysm (AAA). However, whether IH serves as an independent risk factor for AAA development remains to be investigated. Here, we determined the effects of chronic (6 mo) IH on angiotensin (Ang II)-induced AAA development in C57BL/6J male mice and investigated the underlying mechanisms of IH in cultured vascular smooth muscle cells (SMCs). IH increased the susceptibility of mice to develop AAA in response to Ang II infusion by facilitating the augmentation of the abdominal aorta's diameter as assessed by transabdominal ultrasound imaging. Importantly, IH with Ang II augmented aortic elastin degradation and the expression of matrix metalloproteinases (MMPs), mainly MMP8, MMP12, and a disintegrin and metalloproteinase-17 (ADAM17) as measured by histology and immunohistochemistry. Mechanistically, IH increased the activities of MMP2, MMP8, MMP9, MMP12, and ADAM17, while reducing the expression of the MMP regulator reversion-inducing cysteine-rich protein with Kazal motifs (RECK) in cultured SMCs. Aortic samples from human AAA were associated with decreased RECK and increased expression of ADAM17 and MMPs. These data suggest that IH facilitates AAA development when additional stressors are superimposed and that this occurs in association with an increased presence of aortic MMPs and ADAM17, potentially due to IH-induced modulation of RECK expression. These findings support a plausible synergistic link between OSA and AAA and provide a better understanding of the molecular mechanisms underlying the pathogenesis of AAA.NEW & NOTEWORTHY IH facilitates Ang II-induced abdominal aortic diameter expansion and AAA development in C57BL/6J male mice. IH upregulates the expression of specific MMPs such as MMP8, MMP12, and ADAM17. IH directly suppresses RECK expression and increases MMPs activity in SMCs. Human AAA tissues exhibit a downregulation of RECK and an upregulation of ADAM17 and MMPs.
BACKGROUND: Sepsis is a life-threatening condition triggered by uncontrolled immune responses to infection, leading to widespread inflammation, tissue damage, organ dysfunction, and potentially death. The liver plays a crucial role in the immune response during sepsis, serving as a major site for immune cell activation and cytokine production. Liver type 1 innate lymphoid cells (ILCs) consist of NK cells and ILC1s. They maintain the local immune microenvironment by directly eliminating target cells and secreting cytokines. However, the specific roles and pathological changes of liver-resident NK cells and ILC1s during sepsis remain poorly understood.
RESULTS: This study aims to investigate the pathological changes of NK cells and ILC1s, which might contribute the dysfunction of liver. Sepsis mouse model was established by cecal ligation and puncture (CLP). Mouse immune cells from liver were isolated, and the surface makers, gene expression profiles, cytokine response and secretion, and mitochondrial function of NK (Natural Killer) cells and ILC1s (Innate Lymphoid Cell 1) were analyzed. A significant decrease in the number of mature NK cells was observed in the liver after CLP. Furthermore, the secretion of interferon-gamma (IFN-γ) was found to be reduced in spleen and liver NK cells when stimulated by IL-18. Mitochondrial activities in both liver NK cells and ILC1 were found to be increased during sepsis, suggesting an enhanced metabolic response in these cells to combat the infection. However, despite this heightened activity, liver NK cells exhibited a decreased level of cytotoxicity, which might impact their ability to target infected cells effectively. RNA sequencing supported and provided the potential mechanisms for the proinflammatory effects and exhaustion like phenotypes of liver NK cells.
CONCLUSIONS: Sepsis induces dysfunction and exhaustion-like phenotypes in liver NK cells and ILC1, which might further impair other immune cells and represent a potential therapeutic target for sepsis.
The invention relates to a compound Cistanche deserticola tablet. Prostatic hyperplasia is a common disease in elderly men, and is mainly caused by yang acupoint mediation helplessness because of the internal organ deficiency, and no yin transformation and disordered opening and closing because of the kidney deficiency. Symptoms of the prostatic hyperplasia comprise difficult urination, urine discharge failure, penis ache, and urine retention caused by urethra obturation, urine retention in the bladder and underbelly distending pain when the prostatic hyperplasia is severe. The prostatic hyperplasia is treated through turbid yin descending by utilizing qi tonifying, lucidity ascending, qi transformation helping and downward obturation unblocking in the invention. The compound Cistanche deserticola tablet mainly comprises 35% of Cistanche deserticola, 15% of Rhodiola rosea, 10% of Oil Palm Fruit, 7% of root of Urtica dioica L., 5% of Rhizoma Alismatis, 5% of Dioscorea tokoro Makino, 10% of Pygeum Africanum, 2% of Cordyceps sinensis, 2% of lycopene, 2% of Radix Astragali saponin, 5% of Semen Plantaginis, and 2% of total glycoside of ginseng. A case that the prostatic hyperplasia is mainly caused by yang acupoint mediation helplessness because of the internal organ deficiency, and no yin transformation and disordered opening and closing because of the kidney deficiency is considered in the traditional Chinese medicinal science, so the turbid yin descending by utilizing qi tonifying, lucidity ascending, qi transformation helping and downward obturation unblocking is a primary treatment principle in the invention. The above twelve medicines are mixed according to corresponding proportions, undergo ultrafine crushing, and are uniformly stirred to prepare the tablet or a capsule. 1.5-2g of the tablet or the capsule is orally taken each time, and is continuously taken three times a day after each meal by warm water for 6-8 weeks.
The invention discloses health-care wine and a preparation process thereof. The health-care wine is prepared from 80 to 120 grams of medlar, 80 to 120 grams of rhizoma polygonati, 15 to 25 grams of poria cocos, 4 to 6 grams of cinnamon, 8 to 10 grams of Chinese date and 1,000 milliliters of white spirit. The making method is to blend the extracts of the medlar, rhizoma polygonati, poria cocos, cinnamon and Chinese date in the raw materials, which are obtained by a supercritical CO2 extraction or water extraction and alcohol precipitation method or a microwave-assisted extraction technique, with white spirit. The health-care wine has two health-care effects of improving immunity in human body and resisting body fatigue and is free from toxic and side effects and is safe. Compared with the conventional soaking method and the like, the method can improve the concentration of effective ingredients in the product, and reduce the content of ineffective ingredients and the content of harmful ingredients such as heavy metals in traditional Chinese medicinal materials. Thus, the method is more favorable for body health. At the same time, the method can reduce process time to a maximum degree.
Lori Perez will travel to each site from Westat and conduct Review of Draft Focus Groups with adolescents and young adults (n per site = approximately 10 - 15) to collect final feedback on the adolescent friendly version (present key pieces of the adolescent friendly version and obtain feedback on the wording and the illustrations). Based on the focus group feedback, the research team will finalize the adolescent friendly materials.
OBJECTIVES: To determine the association of adequate empirical combination therapy (AECT) with 30-day all-cause mortality in patients with septic shock due to Pseudomonas aeruginosa bloodstream infections (BSI).
METHODS: This multicentre, retrospective cohort study analysed data from 14 public hospitals in Italy, including all consecutive adult patients admitted during 2021-2022 with septic shock due to P. aeruginosa BSI. We compared the outcomes of patients receiving AECT to those on adequate empirical monotherapy (AEMT) using Cox regression analyses.
RESULTS: Of the 98 patients who received adequate empirical antibiotic treatment for septic shock due to P. aeruginosa BSI, 24 underwent AECT and 74 were given AEMT. AECT was associated with a lower 30-day all-cause mortality (25%, six out of 24) compared to AEMT (56.8%, 42 out of 74; P = 0.007). Multivariate Cox regression analysis indicated AECT as the only factor significantly associated with improved survival (aHR 0.30; 95% CI 0.12-0.71; P = 0.006). By contrast, the use of monotherapy or combination therapy in the definitive regimen did not influence mortality (aHR 0.73; 95% CI 0.25-2.14; P = 0.568).
CONCLUSIONS: AECT may be associated with reduced mortality compared to monotherapy in septic shock patients due to P. aeruginosa BSI. However, the administration of definitive adequate monotherapy or combination therapy yields similar outcomes, suggesting that once susceptibility is documented, switching to a single active in vitro drug is safe and feasible. Further studies are recommended to validate these findings.
PURPOSE:To efficiently obtain the compound useful as a raw material for compounded perfumes, etc., by treating a 12-hydroxy-8alpha,12-epoxy-13,14,15,16- tetranorlabdane compound with a Wittig's reagent in the presence of a base in a solvent and subsequently subjecting the reaction. product to a thermal ring-closing reaction. CONSTITUTION:An optically active 12-hydroxy-8alpha,12-epoxy-13,14,15,16- tetranorlabdane of formula I (the waved line exhibits the cis or trans isomer) is reacted with a Wittig's reagent of formula II (R is methyl, ethyl; Ph is phenyl; X is halogen) (e.g. methoxymethyltriphenylphosphonium chloride) in the presence of a base (e.g. sodium hydride) in an organic solvent (e.g. dimethyl sulfoxide), and the formed optically active 8alpha-hydroxy-13-alkoxy-14,15,16-trinorlabda-12-ene compound of formula III is subjected to a thermal ring-closing reaction in the presence of an acid to obtain (-)-8alpha,13-epoxy-14,15,16-trinorlabda-12-ene of formula IV.